Adding plasma HGF to established risk factors substantially improves the risk prediction for an unfavorable prognosis in patients with AIS patients; thus, the results of the present study extend the prognostic significance of HGF in patients with AIS administered t-PA treatment within 24 h poststroke. This evidence concerns the gene HGF and androgen insensitivity syndrome.